American College of Cardiology

The purpose of this study was to evaluate whether extended-duration rivaroxaban reduces the risk of venous and arterial fatal and major thromboembolic events without significantly increasing major bleeding in acutely ill medical patients after discharge.

The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients.

COVID-19 has placed an enormous strain on the healthcare systems of the nations where it has spread widely, with specific implications of the disease on practice in the catheterization laboratory.

As we were planning for ACC.20/WCC in Chicago we noted that American College of Cardiology’s (ACC) Annual Scientific Session is always evolving to make the most out of new technologies, educational formats, new science and more.

Background on Coronavirus epidemic COVID-19 was first reported in late December 2019, originating in Wuhan, China COVID-19 is a betacoronavirus, like SARS and MERS, presenting as viral pneumonia with a wide range of acuity

What is the risk of occult colorectal cancer in patients with atrial fibrillation (AF) treated with oral anticoagulation therapy (OAC) who experience gastrointestinal (GI) bleeding?

Electronic cigarettes or E-cigarettes (EC) are gaining popularity worldwide as an alternative to smoking tobacco cigarettes (TC) with a 55% increase in users between 2013 and 2015 with growth in the United Kingdom occurring fastest in Europe.

Cardiac implantable electronic device infection is a major complication that usually requires device removal. PADIT (Prevention of Arrhythmia Device Infection Trial) was a large cluster crossover trial of conventional versus incremental antibiotics.

Femoral access is the gold standard for transcatheter aortic valve replacement (TAVR). Guidelines recommend reconsidering surgery when this access is not feasible. However, alternative peripheral accesses exist, although they have not been accurately compared with femoral access.

The following are key perspectives from the 2018 multisociety Guideline on the Management of Blood Cholesterol, based on the Top Ten Take Home Messages selected by the Writing Committee.